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Physiological Effects of Electronic Cigarettes: 




Background: Electronic cigarettes represent a new phenomenon in the fight against smoking. While 
they continue to be marketed both as safer than traditional cigarettes and as potential smoking cessation 
tools, little is known about their potential physiological effects.  
Objectives: The purpose of this systematic review was to provide an analysis of the physiological 
effects of e-cigarettes in humans. 
Methods: A search was conducted by two independent authors using PubMed, SCOPUS, Web of 
Science and the Cochrane Library electronic databases (until July 24, 2017 ). Inclusion criteria consisted 
of: English and French language peer-reviewed articles; studies including human participants; objective 
measurements of physiological responses to active e-cigarette smoking; physiological measures obtained 
during or post-smoking and compared to baseline measures. 
Results: Of the 3101 studies investigated, fourteen studies met the inclusion criteria. These studies 
indicated that the short-term (4-20 minutes) use of e-cigarettes resulted in decreases in measures of 
respiratory function such as forced expiratory volume in one second (FEV1), forced vital capacity 
(FVC), forced expiratory flow (FEF) and exhaled carbon monoxide (eCO); as well as increases in 
cardiovascular measures such as heart rate and blood pressure. Exposure to e-cigarettes was found to be 
less harmful than exposure to combustible cigarettes, though not entirely benign. 
Conclusions: Based on the current literature, e-cigarettes do not appear to be as harmful as traditional 
cigarettes. As these devices have only recently become available, it has been impossible to conduct any 
long-term studies into their repercussions. Further studies are needed to gain an understanding of 
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A: Peak late velocity 
Am: Late diastolic peak velocity 
DBP: Diastolic blood pressure 
DT: E wave deceleration time 
E: Peak early velocity 
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eCO: exhaled carbon monoxide 
Em: Early diastolic peak velocity 
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FEF: forced expiratory flow 
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MSNA: muscle sympathetic nerve activity 
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Cigarette smoking is one of the most important modifiable risk factors for a number of chronic 
diseases. Despite this knowledge, the World Health Organization estimates that there are over 1 billion 
smokers worldwide [1]. When lit, conventional tobacco cigarettes rapidly deliver nicotine, a highly 
addictive substance, along with a number of other toxic and carcinogenic chemicals to the body and 
brain [2, 3].  Traditional cigarettes release over 7,000 different compounds into the air; a great many of 
which have been linked to the diseases and premature deaths of over 7 million people each year [1, 3, 4].  
It is this knowledge of the dangers of cigarette smoking that has led to the decrease in smokers since the 
early 1980’s [5, 6]. In fact, 2015 marked the lowest prevalence of cigarette smokers in Canada, 3.9 
million, since it first started being monitored [7].  
 
1.2 Electronic Cigarettes 
The year 2004 saw the advent of the modern electronic cigarette (also known as e-cigarette, e-
cig, electronic nicotine delivery system (ENDS), electronic vaping device or personal vapourizer) [8]. 
Since the inception of the e-cigarette, the number of young adults, aged 20-24, reporting the use of these 
devices has seen a steady increase [5, 9]. According to the Centre for Disease Control (CDC), in 2015, e-
cigarettes were the most commonly used tobacco product among youth in the United States [10, 11]. In 
Canada, a 2013 survey reported that 20.1% of young adults had tried e-cigarettes at least once [12], and 
today, almost 4 million Canadians have tried e-cigarettes [7].  
 
E-cigarettes deliver an aerosol by heating a chemical solution containing glycerol or propylene 
glycol, flavouring, and optionally, nicotine. E-cigarettes have been marketed as a healthier alternative to 
traditional cigarettes and, prior to new regulation, provided a means for smokers to evade many ‘no 
smoking’ laws [13]. In addition, some professionals advocate their use as potential smoking cessation 
tools [14]. There are preliminary studies indicating that the success rate of permanent smoking cessation 
with the use of e-cigarettes can be quite low (1%) and that most people who use e-cigarettes remain 
addicted to nicotine [15]. In addition, some systematic reviews on the use of these devices as smoking 
cessation tools have found that e-cigarettes lead to worse odds of quitting smoking when compared to 
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traditional cessation methods [16, 17]. In contrast, there are other reviews that report that using e-
cigarettes results in equal, if not greater, rates of smoking cessation when compared to nicotine 
replacement therapy (NRT), varenicline or bupropion [18-21].  
 
The suggestion of using e-cigarettes to aid in smoking cessation is based on claims that the 
device user has the ability to choose how much nicotine they will smoke, and therefore allows for the 
gradual weaning off of their nicotine addiction [15, 16, 22]. Despite giving users the ability to choose 
their nicotine usage, nearly 20% of surveyed users were unsure as to the nicotine content of their e-
cigarette [5]. In addition, it is estimated that nearly half of all e-cigarettes contain nicotine despite being 
marketed as non-nicotine containing products [5, 23]. These claims have sparked major debates as to the 
potential harms and benefits of e-cigarettes. Often times the argument in favour of e-cigarettes is based 
on the fact that some do not contain tobacco. The US Food and Drug Administration (FDA), though, has 
made it clear that while these e-cigarettes may not contain tobacco, they do contain a number of 
carcinogens that may be dangerous to humans [24]. Yet, as there has been little to no regulation, the 
levels of toxicants found in e-cigarettes varies, sometimes reaching levels higher than those found in 
traditional cigarettes [25]. The FDA is now in the process of imposing regulations on the manufacturing 
and distribution of e-cigarettes [26]. By the end of 2017, in the United States, e-cigarette manufacturers 
will have to submit health documents and ingredient lists prior to selling them, and by 2019, they will 
have to submit documents specifying the quantities of harmful and potentially harmful constituents [26]. 
Currently, in Canada, eight provinces have put in place regulations to restrict the sale, promotion and use 
of e-cigarettes, though no federal regulation exists at this time [27-30].  
 
In addition to the carcinogens found in e-cigarettes, there is also a major concern regarding the 
vast number (approximately 7,750) of unregulated flavouring agents that can be added to the device [31]. 
In the early 2000’s, strong evidence indicated that certain flavouring agents used in the production of 
popcorn flavouring, when inhaled, were linked to a phenomenon known as bronchitis obliterans in 
factory workers [32]. Bronchitis obliterans, also known as Popcorn Lung, is a non-reversible obstructive 
lung disease causing a dry cough, wheezing and shortening of breath [33]. This disease is thought to be 
caused by the chemical Diacetyl, which has also been found to be present in 75% of e-cigarette flavour 
additives. Consistent with this, recent studies that have found increases in respiratory impedance, flow 
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respiratory resistance, and overall peripheral airway resistance immediately after smoking an e-cigarette 
[24]. Given this information, the need to better understand their effects on health is critical. 
 
At this time, there is little in the way of firm evidence in support of, or against, the use of e-
cigarettes. Due to this lack of evidence, the majority of organizations are recommending the strict 
regulation of e-cigarettes (often adopting combustible cigarette regulations) until further information 
becomes available. In fact, The Forum of International Respiratory Societies released a position 
statement in which they recommend that e-cigarettes be banned or, at the very least, be heavily restricted 
until more is known about the potential dangers of these devices [22]. Their main concerns rest in the 
levels of nicotine, propylene glycol and trace chemicals like quinoline, benzoic acid, and 
diethylcarbonate in these devices and their potential long-term health effects.  
 
There remain many gaps in the knowledge base about e-cigarettes and their physiological effects. 
The aim of this document is to provide a systematic review and meta-analysis of the current literature on 
the effects of smoking electronic cigarettes on physiological parameters in comparison to not smoking e-
cigarettes (e.g. traditional cigarettes, placebos and controls). We hypothesized that: 1) e-cigarettes would 
have deleterious effects on physiological responses, and 2) those effects would be less pronounced than 




This systematic review was conducted in accordance with the preferred reporting items for systematic 
reviews and meta-analysis protocol (PRISMA-P) guidelines (PROSPERO ID: CRD42017062693) [34]. 
 
2.1 Literature Search 
Systematic literature searches were conducted until July 24 2017 to identify research related to e-
cigarettes and their effects on all physiological parameters in human subjects. The following electronic 
databases were used: PubMed, Scopus, The Cochrane Library and Web of Science. The search terms 
used as well as the detailed search strategy used for each database can be found in Appendices A and B. 
Additional articles were identified using the reference sections of eligible articles.  
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2.2 Study Selection and Data Extraction 
 Potential studies were selected in accordance with the following inclusion criteria: 1) English and 
French language peer-reviewed articles; 2) studies including only human participants; 3) studies that 
objectively measured physiological responses to active e-cigarette smoking; 4) physiological measures 
obtained during or post-smoking and compared to baseline or pre-smoking. For this review, only studies 
that measured the effects of the active smoking of e-cigarettes were included. Human studies were 
defined as those with effects being measured in human beings; in vitro, ex vivo and animal studies were 
not included. Passive smoking or exposure to second-hand smoke were not included.  
 
 Two reviewers (ED and CR) independently screened all articles returned by the databases. Initial 
screening of titles and abstracts was conducted. Once the initial abstract screening was completed, the 
full-text of the remaining articles were independently assessed by the two reviewers (ED and CR). Any 
discrepancies were discussed with a third reviewer (SLB). Reviewers then performed an independent 
data extraction of the selected studies. Data extraction was performed using Excel. 
 
 The quality of the chosen studies was evaluated using the Downs and Black Checklist [35]. This 
checklist was adapted to only include those questions relevant to the acute laboratory study design, so 
that a total of 13 of the 27 items (reporting subscale: 1- 4, 6, 8, 10; external validity subscale: 11; internal 
validity subscale: 15, 16, 18, 20, 21) were considered.   
 
2.3 Assessment of Publication Bias 
 To identify potential publication bias, a funnel plot was examined. Symmetrical funnel plots 
indicate a low risk of publication bias, while asymmetrical plots represent greater risk of publication 
bias, often resulting in overestimates of effect size. While symmetry can be indicative of low risk of 
publication bias, it can also indicate heterogeneity among the selected studies or small-study effects. 
 
2.4 Statistical Analysis 
Data were analyzed using Comprehensive Meta-Analysis software (CMA) [36]. A minimum of 
two studies reporting means and standard deviations for the same response were needed in order to 
perform the meta-analysis. Standardized difference in means (SMD) with 95% confidence intervals (CI) 
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were calculated for each response to e-cigarettes. SMDs were evaluated based on the following 
categories: between 0.2 and 0.5 were considered a small effect size, between 0.5 and 0.8 were considered 
moderate, and 0.8 and above was a large effect [37]. The effect size (ES) representing the difference in 
physiological response (heart rate, systolic and diastolic blood pressure) between pre and post cigarette 
smoking was computed using mean changes and p-values. High levels of homogeneity were expected, 
therefore, the fixed effects model was used. Secondary analyses were performed to assess differences 
between e-cigarettes and traditional cigarettes on physiological responses. The moderators used were e-
cigarette and traditional cigarette. Of note: the six unique smoking arms of the Yan et al. study were 
included as separate entries in the meta-analysis and risk of bias assessments.  
 
3.0 RESULTS 
The initial search yielded 9255 articles (see Figure 1); 6124 of which were duplicates or 
descriptions of the same study. After article titles and abstracts were reviewed for adherence to the 
inclusion and exclusion criteria, 26 articles were reviewed in full. A total of 12 studies were excluded 
after full-text review: two studied passive smoking [38, 39]; three lacked objective physiological 
measurements [40-42]; three lacked baseline measures [43-45]; two were retrospective reviews of past 
medical charts [46, 47]; one was an ongoing protocol with no results at this time [48]; and one was 
longitudinal (not experimental) [49]. A total of 14 studies met the inclusion criteria and were retained for 


























































Potentially relevant articles 
identified: 9225 
• PubMed: 1848 
• Cochrane: 127 
• Scopus: 3640 
• Web of Science: 3610 
 
Duplicates: 6124 
Titles and Abstracts 
screened: 3101 
Records excluded: 3075 
• Advertising: 117 
• Animal: 64 
• Case study: 43 
• Cessation: 215 
• Cellular: 117 
• Conference: 37 
• Language: 52 
• Non-Physiological: 887 
• Not e-cigarettes: 452 
• Perceptions: 219 
• Policy: 272 
• Prevalence: 312 
• Reviews: 273 
• Passive exposures: 14 
Articles obtained for 
full text review: 26 

























Records excluded: 12 
• No objective measurement: 3 
• Passive smoking: 2 
• Retrospective: 2 
• Ongoing: 1 
• No baseline: 3 
• Longitudinal: 1 
 7 
3.1 Study Characteristics 
 Table 1 describes the characteristics of the selected studies. All studies reported the sex of the 
participants; two of the studies included only men [54, 56]. The overall percentage of women was 
34.68%. The mean age of the populations was 32.35 years old with a range of 18 [61]  to 65 [56, 61]. 
Smoking status of participants was objectively measured through serum and/or urine cotinine tests in 11 
of the 14 studies [22, 50, 51, 53-60]. The remaining three articles either used self-report [52, 61] or did 
not report how smoking status was verified [24]. 
 
Table 1.  Characteristics of the studies 
First author 
(year) 












Sweden 14 27(5) 35.7 Objective Smoking Cessation 10 
Carnevale 
(2016) 




























Italy 25 28(9) 44.0 Objective Traditional 


















USA 32 33.6(12) 40.6 Objective or 
Self-report 
Traditional 

























Yan (2015) USA 30 38.7(10.77) 52.0 Objective Traditional 




Note: D&B, Downs and Black Checklist [35] (Maximum total score = 13). 
 
3.2 Cigarette Consumption 
Smoking session duration ranged from 5 minutes [22, 24, 53, 62] to 2 weeks [61]. Four studies 
had two arms, comparing an e-cigarette with a traditional cigarette [22, 50, 52, 61]. Two studies, with 2 
arms, compared e-cigarettes at different nicotine concentrations [51, 54]. Three studies compared e-
cigarettes of differing nicotine concentrations with traditional cigarettes [53, 56, 57]. One study 
compared e-cigarettes to both traditional cigarettes as well as a sham cigarette or non-smoking condition 
[55]; and four studies compared e-cigarettes to a sham e-cigarette or non-smoking condition only [24, 
58-60]. Details on smoking protocol and devices used can be found in Table 2. 
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3.3 Physiological Stress Responses 
Below are the detailed results for each physiological measure reported.  
 
3.3.1 Cardiovascular Responses 
 A total of 5 studies measured cardiovascular responses to e-cigarettes [51, 52, 55, 57, 59]. These 
details can be found in Table 3.  
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 Overall, e-cigarettes were found to cause minimal cardiovascular responses. Of the five studies 
that measured heart rate, two found that smoking e-cigarettes caused an increase in heart rate, regardless 
of nicotine concentration [51, 57]. One study found heart rate to decrease when smoking e-cigarettes, 
compared to traditional cigarettes [59]. Only these three studies were meta-analyzed, as neither Cooke et 
al. nor Vansickel et al. provided the necessary information for quantitative analysis [51, 62]. A very 
minor, non-significant effect size was found for the increases in heart rate following the smoking of e-
cigarettes (SMD=0.068; 95% CI -0.046-0.183) [52, 57, 59] (Figure 2a).  
 
Four studies measured blood pressure [51, 52, 57, 59]; three of these studies provided the 
information required for meta-analysis [52, 57, 59]. This found e-cigarettes to increase systolic blood 
pressure (SMD = 0.064; 95% CI -0.049-0.177), though the effect size was minimal and not significant 
(Figure 2b). For diastolic blood pressure, a small, but statistically significant, effect size was found for 
its increase after smoking e-cigarettes (SMD = 0.303; 95% CI 0.181- 0.425) (Figure 2c). Overall, minor 
variations in the length of smoking session did not appear to have an effect on the results obtained. 
 
Figure 2. Forrest plots for studies reporting means and standard deviations; a: heart rate; b: 
systolic blood pressure; c: diastolic blood pressure. 
a. Heart rate 
 
Note: The black diamond at the bottom of the plot indicates the average effect size of the studies. Conditions of 
Yan et al. are as follows: E-Cig A, Classic 2.4% nicotine, ~75% glycerin; E-cig B, Classic 2.4% nicotine, ~50% 
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glycerin, ~20% propylene glycol; E-cig C, Menthol 2.4% nicotine, ~75% glycerin; E-cig D, Classic 1.6% nicotine, 
~75% glycerin; E-cig E, Classic 1.6% nicotine, ~50% glycerin, ~20% propylene glycol. D’Ruiz et el. are: A1, blu 
tobacco rechargeable 24mg; A2, blu cherry rechargeable 24mg; A3, blu cherry disposable 24mg. 
 
b. Systolic blood pressure 
 
Note: The black diamond at the bottom of the plot indicates the average effect size of the studies. Conditions of 
Yan et al. are as follows: E-Cig A, Classic 2.4% nicotine, ~75% glycerin; E-cig B, Classic 2.4% nicotine, ~50% 
glycerin, ~20% propylene glycol; E-cig C, Menthol 2.4% nicotine, ~75% glycerin; E-cig D, Classic 1.6% nicotine, 
~75% glycerin; E-cig E, Classic 1.6% nicotine, ~50% glycerin, ~20% propylene glycol. D’Ruiz et el. are: A1, blu 
tobacco rechargeable 24mg; A2, blu cherry rechargeable 24mg; A3, blu cherry disposable 24mg. 
 
c. Diastolic blood pressure 
 
Note: The black diamond at the bottom of the plot indicates the average effect size of the studies. Conditions of 
Yan et al. are as follows: E-Cig A, Classic 2.4% nicotine, ~75% glycerin; E-cig B, Classic 2.4% nicotine, ~50% 
glycerin, ~20% propylene glycol; E-cig C, Menthol 2.4% nicotine, ~75% glycerin; E-cig D, Classic 1.6% nicotine, 
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~75% glycerin; E-cig E, Classic 1.6% nicotine, ~50% glycerin, ~20% propylene glycol. D’Ruiz et el. are: A1, blu 
tobacco rechargeable 24mg; A2, blu cherry rechargeable 24mg; A3, blu cherry disposable 24mg. 
 
 
 Measures of myocardial function were also assessed [52], see Appendix C. Pressure rate 
product, peak late velocity, E wave deceleration time, late diastolic peak velocity, E/Em, late diastolic 
strain rate, peak early velocity, early diastolic peak velocity, early diastolic strain rate and systolic peak 
velocity were all found to increase, though not significantly, after smoking e-cigarettes. Meanwhile, peak 
ratio, E/Am, global peak longitudinal systolic strain rate, myocardial performance index Doppler flow 
(IVRT), myocardial performance index Doppler tissue (IVRTc) and end-systolic global strain were 
found to decrease after use of e-cigarettes. As with the other markers of myocardial function, changes in 
values after smoking e-cigarettes were not found to be significant. Though not significant, the pattern of 
these results suggest that long term use of e-cigarettes may alter myocardial function in similar ways to 
traditional cigarettes, potentially leading to the development of atherosclerosis and cardiovascular 
disease [52]. 
 
 One study assessed muscle sympathetic nerve activity (MSNA) and vagal cardiac control [51] 
(Appendix C). The authors found that MSNA increased, though not significantly, after use of an e-
cigarette with nicotine. Vagal cardiac control was shown to decrease non-significantly after both nicotine 
free and nicotine testing conditions. The pattern of these results suggests that e-cigarettes induce mild 
sympathoexcitatory responses. 
 
Table 3. Cardiovascular Responses 
Marker Studies Nicotine Content Outcome 
Heart Rate Cooke et al. 2015 
Cooke et al. 2015  
D’Ruiz et al. 2017, E-Cig A1 
D’Ruiz et al. 2017, E-Cig A2 
D’Ruiz et al. 2017, E-Cig A3 
Farsalinos et al. 2014 
Vansickel et al. 2010 
Vansickel et al. 2010 
Yan et al. 2015, E-Cig A 






















Yan et al. 2015, E-Cig C 
Yan et al. 2015, E-Cig D 









Cooke et al. 2015  
Cooke et al. 2015  
D’Ruiz et al. 2017 
D’Ruiz et al. 2017 
D’Ruiz et al. 2017 
Farsalinos et al. 2014 
Yan et al. 2015, E-Cig A 
Yan et al. 2015, E-Cig B 
Yan et al. 2015, E-Cig C 
Yan et al. 2015, E-Cig D 

























Cooke et al. 2015  
Cooke et al. 2015  
D’Ruiz et al. 2017 
D’Ruiz et al. 2017 
D’Ruiz et al. 2017 
Farsalinos et al. 2014 
Yan et al. 2015, E-Cig A 
Yan et al. 2015, E-Cig B 
Yan et al. 2015, E-Cig C 
Yan et al. 2015, E-Cig D 

























Note: Conditions of Yan et al. are as follows: E-Cig A, Classic 2.4% nicotine, ~75% glycerin ; E-cig B, Classic 
2.4% nicotine, ~50% glycerin, ~20% propylene glycol; E-cig C, Menthol 2.4% nicotine, ~75% glycerin; E-cig D, 
Classic 1.6% nicotine, ~75% glycerin; E-cig E, Classic 1.6% nicotine, ~50% glycerin, ~20% propylene glycol. 
Conditions of D’Ruiz et al.: A1, blu tobacco rechargeable 24mg; A2, blu cherry rechargeable 24mg; A3, blu 
cherry disposable 24mg. 
, Increase; , Decrease;   , No change; *, change was statistically significant. 
 
3.3.2 Respiratory Responses 
 A total of eight studies [22, 24, 54-59] assessed the effects of e-cigarettes on respiratory 
responses. Details of the main measurements and outcomes can be found in Table 4.  
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Insufficient data was provided on respiratory measures to perform a meta-analysis. As seen in 
Table 4, fractional exhaled nitric oxide (FeNO) was found to increase slightly (p=0.03) after smoking e-
cigarettes in one study [54], remain unchanged in two studies [22, 58], and decrease (p=0.005 and 0.007) 
in two other studies [24, 53]. No meta-analysis was performed on FeNO as neither means nor standard 
deviations were reported in three of the five studies. Fractional expired carbon monoxide (FeCO) and 
expired carbon monoxide (eCO) were not affected by e-cigarettes [22, 54-57], regardless of nicotine 
content in all except one study, which found a decrease in eCO when using e-cigarettes [59].  
 
As shown in Appendix C, both forced expiratory volume in 1 second (FEV1)– the maximum 
amount of air one can exhale in the first second of a forced vital capacity (FVC) test – and forced 
expiratory flow at 25% (FEF25) – the average forced expiratory flow during the mid-portion of the FVC 
– showed conflicting results among studies measuring them [22, 59]. One study evaluated the effects of 
e-cigarettes on respiratory mechanics, finding that respiratory impedance (Z5Hz), respiratory resistance 
(R5Hz, R10Hz and R20Hz), respiratory reactance (X20Hz), peripheral resistance and central resistance 
increased after smoking e-cigarettes [24]. Respiratory reactance measures (X5Hz and X10Hz) and 
resonant frequency showed decreases after smoking e-cigarettes [24]. Qualitative evaluation of the 
collective data suggests that smoking e-cigarettes decreased respiratory measures. 
 
Table 4. Respiratory Responses 
Marker Studies Nicotine Concentration Outcomes 
FeNO Antoniewicz et al. 2016 
Ferrari et al. 2015  
Schober et al. 2014  
Schober et al. 2014  
Vardavas et al. 2012 
Marini et al. 2014  















eCO D’Ruiz et al. 2017, E-Cig A1 
D’Ruiz et al. 2017, E-Cig A2 
D’Ruiz et al. 2017, E-Cig A3 
Ferrari et al. 2015 
Schober et al. 2014 














Vansickel et al. 2010  
Vansickel et al. 2010 
Walele et al.2016 
Yan et al. 2015, E-Cig A 
Yan et al. 2015, E-Cig B 
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Note: FeNO, fractional exhaled nitric oxide; eNO, exhaled nitric oxide; eCO, exhaled carbon monoxide. 
Conditions of Yan et al. are as follows: E-Cig A, Classic 2.4% nicotine, ~75% glycerin ; E-cig B, Classic 2.4% 
nicotine, ~50% glycerin, ~20% propylene glycol; E-cig C, Menthol 2.4% nicotine, ~75% glycerin; E-cig D, 
Classic 1.6% nicotine, ~75% glycerin; E-cig E, Classic 1.6% nicotine, ~50% glycerin, ~20% propylene glycol. 
Conditions of D’Ruiz et el. are: A1, blu tobacco rechargeable 24mg; A2, blu cherry rechargeable 24mg; A3, blu 
cherry disposable 24mg. 
, Increase; , Decrease;   , No change. 
 
3.3.3 Other Responses 
 One study looked at both immune and hematological responses to smoking e-cigarettes [56]. 
There was found to be no significant acute effects of e-cigarettes on any of the responses measured. 
Endothelial progenitor cell (EPC) and microvesicle levels were measured in one study, finding 
significant increases in EPC levels (p=0.003) as well as CD144+CD62E (p=0.038) following exposure 
to e-cigarettes [58]. One study looked at the effects of smoking e-cigarettes on oxidative stress [50]; 
serum soluble NOX2-derived peptide (sNOX2-dp), a marker of NADPH oxidase activation, increased 
significantly after smoking e-cigarettes (p<0.001). The same was found for 8-iso-prostaglandin F2α, 
which also showed a significant increase (p<0.001) after exposure to e-cigarettes. Furthermore, nitric 
oxide bioavailability and vitamin E significantly decreased after participants smoked e-cigarettes [50]. 
This study also evaluated the effects of e-cigarettes on endothelial function. Flow-mediated dilation 
(FMD), a marker used to assess endothelial function, was found to decrease after smoking e-cigarettes 
(p<0.001) [50]. One study, analyzing a number of biomarkers of exposure to harmful or potentially 
harmful constituents, found significant decreases in all markers following e-cigarette use [60]. Gingival 
crevicular fluid and gum bleeding upon probing were found to increase post e-cigarette exposure [61]. 
Further details on other responses reported in these studies can be found in Appendix C. 
 
 16 
3.3.4 Physiological Effects of Traditional Cigarettes 
Traditional cigarettes were, generally, found to have greater effects on physiological responses 
than e-cigarettes. In general, exposure to traditional cigarettes resulted in greater increases in 
cardiovascular measures, more significant changes in myocardial function, greater decreases in 
respiratory measures such as FEV1 and FEF25, as well as increases in CO production and markers of 
oxidative stress. 
 
Traditional cigarettes were found to increase heart rate a small amount (SMD=0.290; 95% CI 
0.123-0.458) [52, 57, 59]. The difference between e-cigarettes and traditional cigarettes for heart rate 
was statistically significant with a p-value of 0.032. Of the three studies that measured blood pressure 
[52, 57, 59], two found traditional cigarettes to increase systolic blood pressure to a greater degree than 
e-cigarettes, while one found traditional cigarettes to decrease systolic blood pressure (SMD = -0.110; 
95% CI -0.283-0.063) with a non-significant difference between groups (p=0.100). With regards to 
diastolic blood pressure, a moderate effect size was found for its increase when smoking traditional 
cigarettes (SMD = 0.336; 95%CI 0.163-0.508), though the difference between groups was non-
significant (p=.760).  
 
 Traditional cigarette use resulted in larger negative changes in myocardial function than did e-
cigarettes [52]. E-wave deceleration time, peak ratio, E/Am, peak early velocity, early diastolic peak 
velocity, early diastolic strain rate and global peak longitudinal systolic strain rate were found to 
decrease after use of traditional cigarettes [52]. Other measures were found to produce opposite effects 
for traditional cigarettes compared to e-cigarettes: myocardial performance index Doppler flow (IVRT), 
myocardial performance index Doppler tissue (IVRTc) and end-systolic global strain increased after 
smoking traditional cigarettes. Finally, systolic peak velocity remained unchanged by traditional 
cigarettes.  
  
 FeNO and eNO were shown to decrease after the use of traditional cigarettes though these 
changes were comparable to those found after smoking e-cigarettes [22, 53]. In contrast to e-cigarettes, 
measures of fractional and expired carbon monoxide (eCO) were increased after smoking traditional 
cigarettes [22, 54-56]. FEV1 and FEF25 decreased significantly for traditional cigarettes (p=.037 for all) 
in smokers but did not show significant decreases in non-smokers [22].  
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A single study evaluated oxidative stress markers [50]. Serum Soluble NOX2-derived peptide 
(sNOX2-dp), a marker of NADPH oxidase activation, increased significantly after smoking traditional 
cigarettes (p<.001). The same was found for 8-iso-prostaglandin F2α, which also showed a significant 
increase (p<.001) after exposure to traditional cigarettes. Both nitric oxide bioavailability and vitamin E 
significantly decreased after smoking traditional cigarettes [50]. Overall, e-cigarettes showed a 
significantly less detrimental impact on levels of sNOX2-dp (p=.001), 8-iso-prostaglandin F2α (p=.046), 
and NO bioavailability (p=.001) compared to traditional cigarettes. Flow-mediated dilation (FMD), a 
marker used to assess endothelial function, was found to decrease significantly in smokers of both 
traditional cigarettes and e-cigarettes(p<.001) [50]. Meta-analysis of, and further details on, responses to 
traditional cigarettes can be found in Appendices D and E. 
 
3.4 Publication Bias and Assessment of Study Quality 
 Figure 3 represents the funnel plot of the SMDs and standard errors for all studies evaluating 
heart rate, systolic blood pressure and diastolic blood pressure for electronic cigarettes. Funnel plots for 
the evaluation of traditional cigarettes can be found in Appendix F. Assessment of the funnel plots 
suggests risk of publication bias. 
 
Figure 3. Funnel plot for studies assessing publication bias; heart rate; systolic blood pressure; and 
diastolic blood pressure 
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Study quality was rated using a modified Downs and Black Checklist. Final scores ranged from 
11 to 13 (mean [M] ± standard deviation [SD] = 11.5 ± 0.85) and are reported in Table 1. All studies 
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received high scores, with two receiving 10/13 [58, 61], four receiving 11/13 [22, 50, 55, 56], seven 
receiving 12/13 [24, 51-54, 59, 60], and one receiving 13/13 [57]. Over half of the studies (8/14) did not 
comment on whether or not they were blinded [22, 24, 53-56, 59, 60]. Six out of ten studies did not 
provide information regarding the representativeness of their samples (ex. “Were the subjects asked to 
participate in the study representative of the entire population from which they were recruited?”) [22, 50, 
52, 55, 58, 61]. 
 
4.0 DISCUSSION 
 The purpose of this systematic review was to provide a synthesis of the physiological effects of 
e-cigarettes in humans. An extensive literature search performed by two independent researchers resulted 
in fourteen studies assessing the physiological effects of e-cigarettes. As hypothesized, it was found e-
cigarettes are not benign and exposure to their vapour does affect numerous physiological systems 
warranting further research. Also as expected, the physiological effects of e-cigarettes were less severe 
than those of traditional cigarettes. 
 
4.1 Physiological Effects of E-cigarettes 
Findings suggest that the effects of e-cigarettes, while not as severe as those from conventional 
cigarettes, can trigger harmful physiological reactions. E-cigarettes were shown to lead to an immediate, 
though not statistically significant, increase in heart rate and blood pressure. The consequences of these 
increases in heart rate and blood pressure are potentially significant when considering long-term use of 
e-cigarettes. Increased blood pressure reactivity is associated with changes in alpha and beta-
adrenoceptor sensitivity, endothelial dysfunction, higher vascular resistance and vascular remodeling 
[63]. These associations may explain why long term increased blood pressure reactivity has been linked 
to incident hypertension, incident cardiovascular disease, myocardial infarction and stroke [63, 64]. 
Meanwhile, elevated heart rate over the long term has been linked to an increased risk of cardiovascular 
related death and all-cause mortality [65]. In fact, for every increase in heart rate of 10 bpm, the chances 
of cardiovascular related death increases by 25%, while all-cause mortality increases by 27%. While the 
heart rate increases presented in this review are not of this magnitude, this information is crucial in 
understanding the potential for increased disease risk over the long term as persistent elevated heart rate 
is also linked to the development of arthrosclerosis and arrhythmias [65].  
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 When looking at the findings in Yan et al., it is clear that e-cigarettes B and C produced the 
largest changes in heart rate [57]. This may be due to the effects of nicotine, as it has been shown to 
cause an immediate increase in cardiovascular responses such as heart rate, blood pressure and 
myocardial contractility [66]. However, there were three products containing the highest level of nicotine 
concentration (2.4%: products A, B and C), suggesting there may be other explanations, in addition to 
nicotine, for the larger increases in heart rate. When comparing products B and C, device C has the most 
sizeable effect on heart rate (SMD=0.62); e-cigarette C was also the only menthol-flavoured cigarette. It 
is possible that the addition of menthol to the device played a role in the greater increases in heart rate. 
Currently the research regarding menthol and its effects on cardiovascular responses is inconclusive, 
with a number of studies presenting evidence that menthol flavouring in cigarettes leads to worse 
responses when compared to cigarettes without menthol [67, 68].  
 
A slight decrease in FeNO was also shown as a result of nicotine-containing e-cigarette smoking. 
FeNO is known to be sensitive to eosinophilic inflammation, airway caliber, mucus production, 
oxidative stress and enzyme activity, all of which may be affected by smoking e-cigarettes. These short 
term reductions can be seen after as little as 5 minutes of smoking when the decrease in FeNO occurs in 
conjunction with increases in lung flow resistance at a number of different frequencies [24]. Nitric oxide 
plays a significant role in physiological processes such as vascular regulation, neurotransmission, host 
defense and cytotoxicity [69]. It has also been identified as a marker associated with airway diseases 
related to smoking [24]. The reduction in FeNO immediately after smoking e-cigarettes indicates that 
pulmonary homeostasis may be negatively affected [70-72]. The reduction in FeNO may be due to a 
common substance in e-cigarettes, propylene glycol. Past studies have shown that frequent exposure to 
inhalation of these vapours in other contexts (e.g., theatrical smoke), is associated with acute cough and 
decreased lung function [73-75]. Increases in the circulating markers of oxidative stress [50], s-NOX2-
dp and 8-iso-prostaglandin F2α were also observed. This was in addition to a reduction in NO 
bioavailability and FMD. eCO measures remained relatively unchanged among e-cigarette users in most 
studies compared to the significant increases seen with traditional cigarettes [22, 54, 56, 57, 59, 62].  
 
Taken together, these results suggest that smoking e-cigarettes may activate the sympathetic 
nervous system (SNS). The increases in heart rate and blood pressure is likely due, in part, to nicotine, 
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which causes vasoconstriction and stimulation of the adrenal medulla, releasing epinephrine and 
norepinephrine[57]. This release of norepinephrine induces a beta-adrenoceptor-mediated increase in 
heart rate as well as an alpha-adrenoceptor-mediated increase in vasomotor tone, and by consequence, 
blood pressure [66]. This upregulation of the SNS has previously been shown to last up to 24 hours after 
smoking traditional cigarettes [76], though it’s length has not yet been studied in e-cigarettes. This is in 
line with the reduction in FeNO, which, when levels decrease, can cause an increase in levels of 
sympathetic nerve activity [77]. This reduction in NO has also been identified as a pathway through 
which oxidative stress increases blood pressure via the SNS [78]. Of note, the FeNO response to e-
cigarettes seems to be almost comparable to that of traditional cigarettes [53]. The results presented here 
are concerning, as similar, though more prominent, activation of the SNS is seen when smoking 
traditional cigarettes [79]. While the magnitude of these changes may not be large at this time, the effects 
being seen warrant future research. 
 
4.2 Methodological Implications and Recommendations 
 There are a number of inconsistencies among the articles assessing the impact of e-cigarettes on 
physiological responses. Methodological factors such as the relatively short smoking sessions, the small 
sample sizes, and standardization of smoking may have influenced the results and contributed to some of 
these inconsistencies. This section aims to account for some of these factors and make recommendations 
for future studies.  
 
4.2.1 Length of Smoking Sessions 
 The smoking sessions in the studies assessed ranged from 5 minutes [22, 24, 53, 55] to two 
weeks [61]. When one considers the amount of time the average smoker spends smoking, it can be 
difficult to expect immediate health repercussions when exposing never-smokers to e-cigarettes for a 
short period of time. The use of more standardized lengths of e-cigarette exposure would be useful in 
creating consistency within the research, though, in the studies included here there was no major 
difference in response between the different lengths of interventions.  
 
4.2.3 Standardization of Inhalations (vapes) 
 Many studies in this review used ad lib smoking during their interventions. While this method 
does provide a more realistic measure of one’s day to day smoking, there is no way to ensure that 
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participants are inhaling the same, or even similar, amounts of the vapour. One study addressed this issue 
by having participants partake in both a controlled smoking session as well as an ad lib session [57]. 
This study found that, when smoking traditional cigarettes, only 1 cigarette was smoked during the 
controlled session compared to an average of 3.6 cigarettes during the ad lib session. The use of both 
controlled and ad lib smoking would be beneficial for future studies, as controlled use allows for 
exposure standardization while ad lib sessions allow for more generalizable results reflective of real-life 
use.  
 
4.2.2 Sample Size 
 Most studies indicated their small sample sizes as being their main methodological limitation. 
Some studies were unsuccessful with recruitment and obtaining a representative sample, as many 
volunteers for e-cigarette studies, are, in fact, people with intentions to quit smoking [49]. It is important 
that future studies make use of larger sample sizes in order to obtain a more accurate and precise picture 
of the physiological effects of smoking e-cigarettes. 
 
4.3 Limitations and Strengths of the Present Review 
 There are several limitations to this review that should be noted. First, and perhaps most obvious, 
is the limited number of studies eligible for this review. To date, there are not many published 
experimental studies looking at the physiological effects of e-cigarettes. While this number is on the rise, 
the results presented here may not be generalizable to the larger population of e-cigarette users. Second, 
this review makes use of proxy physiological measures and does not capture direct health changes. In 
order to capture these health changes, such as the development of cardiovascular disease, longitudinal 
studies would be necessary.  
 Despite these limitations, this systematic review also has important strengths. This review 
explored a wide range of physiological responses to e-cigarettes including respiratory, cardiovascular, 
hematological and immunological. Furthermore, the systematic process followed for this review offers 




 To date, though there are very few studies, e-cigarettes seemed to elicit negative physiological 
responses similar to, though of a lower magnitude, than traditional cigarettes (Figure 4). It is likely that 
some of these responses, such as the increases in heart rate, are, in part, the result of nicotine 
consumption and in general, these responses seem to indicate a disruption in the SNS. Furthermore, the 
often toxic and unknown constituents of e-liquids could also be responsible for the effects seen here [80, 
81]. E-cigarettes represent a major unknown to the fields of research and healthcare. The challenge is to 
build upon these first studies to learn more about the lasting effects of these devices.  
 
Figure 4. Summary of the main physiological responses to e-cigarettes 
 



















Note: This summary of the physiological responses to e-cigarette use is based on at least two consistent 
studies. HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; eCO, exhaled 
carbon monoxide; FeNO, fraction exhaled nitric oxide. 
↑, increase; ↓, decrease,  , no change. * indicates statistical significance. 
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5.1 Future Directions 
This review highlights the need for research into the long term effects of e-cigarettes on 
physiological responses. It can take up to 20 years of exposure for the effects of traditional cigarettes to 
become apparent; it cannot be expected that the effects of e-cigarettes will be identifiable immediately. 
While the information presented here is vital, studies into the long term health effects would fill many 
gaps with regards to the health, safety and future uses of e-cigarettes. 
 
5.2 Clinical Implications 
 In sum, short-term use of e-cigarettes appears to result in less severe physiological changes than 
those observed with traditional cigarettes. While this seems to indicate that e-cigarettes are a safer 
alternative to traditional cigarettes, they are certainly not benign and it is of the utmost importance that 
their long-term effects be examined. Based on these results, e-cigarettes may be a viable option for 
smoking cessation with the help of healthcare professionals though it is important the e-cigarettes do not 
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7.1 Appendix A: Data search strategies presented by database 
 
PubMed 
Build a search library of the relevant search terms. 
Create an advanced search, ADD search 1 (e-cigarette terms) with single physiological terms. 
Example 
Search: (((((((electronic cigarette[Title/Abstract]) OR e-cigarette[Title/Abstract]) OR e-
cig[Title/Abstract]) OR electronic nicotine delivery system[Title/Abstract]) OR personal 
vaporizer[Title/Abstract]) OR personal vapourizer[Title/Abstract])) AND safety 
 
Web of Science 
Build a search library of e-cigarette terms (#1) using “Title, Abstracts, Keywords” 
Create an advanced search combining #1 and single physiological search terms 
 
Scopus 
Build a search library of the relevant search terms. 
Create an advanced search, ADD search 1 (e-cigarette terms) with single physiological terms. 
Example 
Search: (((((((electronic cigarette[Title/Abstract]) OR e-cigarette[Title/Abstract]) OR e-
cig[Title/Abstract]) OR electronic nicotine delivery system[Title/Abstract]) OR personal 
vaporizer[Title/Abstract]) OR personal vapourizer[Title/Abstract])) AND safety 
 
The Cochrane Library 







































7.3 Appendix C: Additional responses to e-cigarettes 
 
 
Table S1. Other cardiovascular responses to e-cigarettes 
 
First Author (year) Nicotine Conc. Markers Outcome 








































Note: MSNA, muscle sympathetic nerve activity; VCC, vagal cardiac control; LV, left ventricular; 
LAAD, left atrial antero-posterior diameter; PRP, pressure rate product; E, peak early velocity; A, peak 
late velocity; E/A, peak ratio; DT, E wave deceleration time; IVRT, isovolumetric relaxation time; 
IVRTc, corrected to heart IVRT; Sm, systolic peak velocity; Em, Early diastolic peak velocity; Am, late 
diastolic peak velocity; MPI, myocardial performance index (Doppler flow); MPIt, myocardial 
performance index (Doppler tissue); GS, end-systolic global strain; SRs, global peak longitudinal 
systolic strain rate; SRe, early diastolic strain rate; SRa, late diastolic strain rate. 














Table S2. Other respiratory responses to e-cigarettes 
 
First Author (year) Nicotine Conc. Markers Outcome 








































Note: FEV1, Forced expiratory volume in 1 second; FVC, Forced vital capacity; PEF, peak expiratory 
flow; FEF, forced expiratory flow; FeNO, fractional exhaled nitric oxide; FeCO, fractional exhaled 
carbon monoxide; eNO, exhaled nitric oxide; eCO, exhaled carbon monoxide; UF2, unflavoured liquid 
with 2% nicotine; FL2, flavoured liquid with 2% nicotine; Z5Hz, respiratory impedance; R5/10/20Hz, 
respiratory resistance; X5/10/20Hz, respiratory reactance, Fres., resonant frequency;  res., resistance. 



















Table S3. Other responses to e-cigarettes 
First Author (year) Nicotine Conc. Markers Outcome 










































































Note: sNOX2-dp, serum soluble NOX2-derived peptide; 8-iso-PGF2⍺, 8-iso-prostaglandin F2⍺; FMD, 
flow-mediated dilation; WBC, White blood cells; RBC, red blood cells; MCV, mean corpuscular 
volume; MCHC, mean corpuscular hemoglobin concentration;  






7.4 Appendix D: Meta-analysis of effects of traditional cigarettes 
 
Figure S1. Cardiovascular effects of traditional cigarettes: a, heart rate; b, systolic blood pressure; c, 















































7.5 Appendix E: Physiological effects of traditional cigarettes 
 
 
Table S4. Cardiovascular effects of traditional cigarettes 
First Author (year) Nicotine Conc. Markers Outcome 










































Vansickel et al. (2010) Own brand HR  






Note: HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; MSNA, muscle 
sympathetic nerve activity; VCC, vagal cardiac control; LV, left ventricular; LAAD, left atrial antero-
posterior diameter; PRP, pressure rate product; E, peak early velocity; A, peak late velocity; E/A, peak 
ratio; DT, E wave deceleration time; IVRT, isovolumetric relaxation time; IVRTc, corrected to heart 
IVRT; Sm, systolic peak velocity; Em, Early diastolic peak velocity; Am, late diastolic peak velocity; 
MPI, myocardial performance index (Doppler flow); MPIt, myocardial performance index (Doppler 
tissue); GS, end-systolic global strain; SRs, global peak longitudinal systolic strain rate; SRe, early 
diastolic strain rate; SRa, late diastolic strain rate. 









Table S5. Respiratory effects of traditional Cigarettes 
First Author (year) Nicotine Conc. Markers Outcome 


















Marini et al. (2014) Own brand eNO  
Vansickel et al. (2010) 1.06mg eCO  
Walele et al. (2016) 0.6mg eCO  
Yan et al. (2015) 0.8mg eCO  
Note: FEV1, Forced expiratory volume in 1 second; FVC, Forced vital capacity; PEF, peak expiratory 
flow; FEF, forced expiratory flow; FeNO, fractional exhaled nitric oxide; FeCO, fractional exhaled 
carbon monoxide; eNO, exhaled nitric oxide; eCO, exhaled carbon monoxide; UF2, unflavoured liquid 
with 2% nicotine; FL2, flavoured liquid with 2% nicotine; Z5Hz, respiratory impedance; R5/10/20Hz, 
respiratory resistance; X5/10/20Hz, respiratory reactance, Fres., resonant frequency;  res., resistance. 





Table S6. Other responses of traditional cigarettes 
First Author (year) Nicotine Conc. Markers Outcome 














Note: sNOX2-dp, serum soluble NOX2-derived peptide; 8-iso-PGF2⍺, 8-iso-prostaglandin F2⍺; FMD, 
flow-mediated dilation; WBC, White blood cells; RBC, red blood cells; MCV, mean corpuscular 
volume; MCHC, mean corpuscular hemoglobin concentration;  










7.6 Appendix F: Funnel plots for traditional cigarettes 
 
























Std diff in means
Funnel Plot of Standard Error by Std diff in means
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Std diff in means
Funnel Plot of Standard Error by Std diff in means
